Innovation | Novartis United States of America

Media Release
Jun 02, 2008
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
Media Release
Oct 08, 2008
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Media Release
Sep 13, 2008
RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
Media Release
Sep 09, 2008
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
Media Release
Dec 20, 2008
Video: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
Media Release
Dec 13, 2008
RAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Media Release
Nov 10, 2008
Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
Media Release
Jul 21, 2009
FDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Media Release
Jun 18, 2009
Video: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
Media Release
Apr 30, 2009
Video: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
Media Release
Aug 27, 2010
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Media Release
May 19, 2010
US Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US

‹ Previous page
1
…
27
28
29
30
31
32
33
…
49
› Next page